Surgical Innovations Group (LSE:SUN) EBIT: £-0.88 Mil (TTM As of Dec. 2025)

What is Surgical Innovations Group EBIT?

Surgical Innovations Group LSE:SUN EBIT is £-0.88 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Surgical Innovations Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was £-0.94 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.88 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Surgical Innovations Group's annualized ROC % for the quarter that ended in Dec. 2025 was -19.20%. Surgical Innovations Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -54.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Surgical Innovations Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -20.50%.

Surgical Innovations Group (LSE:SUN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Surgical Innovations Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-1.878 * ( 1 - 5.08% )	/	( (10.541	+	8.024)	/ 2 )
=	-1.7825976	/	9.2825
=	-19.20 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.5	-	1.42	-	( -0.461	-	max(0, 2.248	-	4.741	+	-0.461	))
=	10.541

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.641	-	2.804	-	( 0.813	-	max(0, 3.434	-	5.096	+	0.813	))
=	8.024

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Surgical Innovations Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.878	/	( ( (1.287 + max(3.427, 0))	+	(1.122 + max(1.1, 0)) )	/	2 )
=	-1.878	/	( ( 4.714	+	2.222 )	/	2 )
=	-1.878	/	3.468
=	-54.15 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.602	+	2.6	+	0)	-	(1.42	+	0	+	0.355)
=	3.427

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.631	+	2.193	+	0.336)	-	(2.804	+	0	+	0.256)
=	1.1

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Surgical Innovations Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-0.878	/	4.283
	=	-20.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Innovations Group EBIT Related Terms

Surgical Innovations Group EBIT Historical Data

* Premium members only.

The historical data trend for Surgical Innovations Group's EBIT can be seen below:

Surgical Innovations Group EBIT Chart

Surgical Innovations Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-0.46

0.04

-0.60

-1.95

-0.88

Surgical Innovations Group Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-0.29	-0.43	-1.52	0.06	-0.94

LSE:SUN vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Surgical Innovations Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surgical Innovations Group EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surgical Innovations Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Surgical Innovations Group's EV-to-EBIT falls into.

Save Embed

Surgical Innovations Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.88 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of £-0.88 Mil mean?

Surgical Innovations Group (LSE:SUN) has a EBIT of £-0.88 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Surgical Innovations Group.

Is Surgical Innovations Group's EBIT too high?

Surgical Innovations Group's current EBIT is £-0.88 Mil.

How does Surgical Innovations Group's EBIT compare to ABT and SYK?

Surgical Innovations Group's EBIT of £-0.88 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Surgical Innovations Group. Surgical Innovations Group's current EBIT is £-0.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Surgical Innovations Group stock overvalued right now?

Based on GuruFocus' analysis, Surgical Innovations Group (LSE:SUN) is currently considered Possible Value Trap. The stock's GF Value™ is £0.01, compared to a current price of £0.00 — trading 52.5% below its estimated fair value. The current EBIT is £-0.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current EBIT is £-0.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surgical Innovations Group Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LSE:RUA ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA STE ZBH XSWX:SOON SHSE:688271 LSE:SN.PEN TSE:7733 GMED PODD

Address Clayton Wood House, 6 Clayton Wood Bank, Leeds, GBR, LS16 6QZ

Website https://www.sigroupplc.com

Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.